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Abstract
CD31, an immunoglobulin-like molecule expressed by leukocytes and endothelial cells, is thought to contribute to the
physiological regulation T cell homeostasis due to the presence of two immunotyrosine-based inhibitory motifs in its
cytoplasmic tail. Indeed, loss of CD31 expression leads to uncontrolled T cell-mediated inflammation in a variety of
experimental models of disease and certain CD31 polymorphisms correlate with increased disease severity in human graft-
versus-host disease and atherosclerosis. The molecular mechanisms underlying CD31-mediated regulation of T cell
responses have not yet been clarified. We here show that CD31-mediated signals attenuate T cell chemokinesis both in vitro
and in vivo. This effect selectively affects activated/memory T lymphocytes, in which CD31 is clustered on the cell membrane
where it segregates to the leading edge. We provide evidence that this molecular segregation, which does not occur in
naı¨ve T lymphocytes, might lead to cis-CD31 engagement on the same membrane and subsequent interference with the
chemokine-induced PI3K/Akt signalling pathway. We propose that CD31-mediated modulation of memory T cell
chemokinesis is a key mechanism by which this molecule contributes to the homeostatic regulation of effector T cell
immunity.
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Introduction
CD31, or platelet endothelial cell adhesion molecule-1 (PE-
CAM-1) is a member of the immunoglobulin gene superfamily
expressed at high density at the lateral borders of endothelial cells
and at a lower density on the surface of hematopoietic cells
including T lymphocytes [1].
CD31–deficient mice exhibit a very mild phenotype and have
normal numbers of T cells [2]. However, genetic deletion of CD31
leads to exaggerated disease severity in inducible experimental
models of T cell-mediated inflammation, including experimental
autoimmune encephalomyelitis (EAE) and collagen-induced
arthritis (CIA) [3,4], suggesting that CD31 signals play a functional
regulatory role under conditions of immunological stress. The
immunoregulatory role of CD31 interaction has recently begun to
be appreciated also in human diseases. Loss of CD31 expression
by CD4+ T cells correlates with increased size of atherosclerotic
aortic aneurism size, a condition in which T cell immunity is a
well-established pathogenic factor [5]. In addition, single nucle-
otide polymorphisms of CD31 encoding amino acid substitutions
at positions affecting the binding site [6] and the intracellular
ITIMs [7] are associated with increased severity of graft-versus-
host disease after hematopoietic stem cell transplantation
[8,9,10,11,12] and atherosclerosis [7,13]. Although T cell-medi-
ated inflammation contributes to the pathogenesis of both these
conditions, the molecular mechanisms underlying this link are at
present unclear.
The immunoregulatory activity of CD31 has been correlated
with the attenuation of T Cell Receptor (TCR) signalling and
reduced Zap-70 phosphorylation, mediated by phosphatases
recruited by its ITIM motifs [14,15], which results in the
inhibition of T cell expansion and effector function [15]. This
effect however cannot fully account for the uncontrolled inflam-
mation observed in diseased CD312/2 mice, as exaggerated
CD312/2 T cell expansion is counterbalanced by enhanced
activation-induced T cell death [15,16].
Enhanced T cell extravasation to non-lymphoid target tissue is a
key feature of inflammation as observed in murine models of
autoimmunity induced in CD31-deficient mice [3,4]. It has been
suggested that loss of junction integrity by vascular endothelium
lacking CD31 expression at non-lymphoid sites of inflammation
[17] might trigger this effect. However, the lack of other cardinal
signs of vascular leakage in CD31-deficient mice led us to
hypothesize that CD31 signalling might directly regulate intrinsic
T cell motility under inflammatory conditions.
Inflammatory chemokines are key mediators of T cell infiltra-
tion of target tissue [18]. We therefore sought to investigate the
effect of CD31 deficiency on T cell responses to chemokines both
in vitro and in vivo. We here show that CD31 signals modulate
chemokinesis in activated, but not naı¨ve, T lymphocytes. This
effect depends on CD31 membrane clustering and segregation on
the memory T cell leading edge, cis-CD31 engagement on the
same membrane and subsequent interference with the PI3K/Akt
signalling pathway.
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Results
CD31 Regulates Chemokine-induced T Cell Migration in
vitro and in vivo
In contrast to the increased T cell infiltration of inflamed target
tissue by activated CD312/2 T cells, cellular composition and
architecture of secondary lymphoid tissue appears to be normal in
CD312/2 mice [2]. In addition, localization of adoptively
transferred wild-type (WT) and CD312/2 naı¨ve T cells to the
spleen is comparable [19]. These observations suggest that
migration of naı¨ve and memory T lymphocytes is differentially
regulated by CD31 signals.
To test this hypothesis, transwell-based assays were set up to
compare chemokinesis of WT and CD31-deficient naı¨ve or
memory T lymphocytes. Comparison of adhesion and chemokine
receptors (including CCR7 and CXCR3) and activation markers
expression by naı¨ve and activated T cells did not reveal any
difference between WT and CD312/2 T cells (Figure S1). The
chemokine ligands for CCR7 and CXCR3 - characteristically
expressed by naı¨ve and activated T cells respectively - were used to
assess chemokinetic responses by WT and CD312/2 T cells. As
it is shown in Figure 1a, CD312/2 naı¨ve T cell migration in
response to the chemokines CCL19 and CCL21 was comparable
to that by WT T lymphocytes. In contrast, migration of CD31-
deficient memory T cells (HY-specific T cell lines) to the
chemokine CXCL10 was significantly increased compared to that
by their WT counterpart (Figure 1b). This effect was not
CXCL10-specific as enhanced chemokinesis by activated T cells
to CXCL12 was also observed (Figure S2).
To verify whether this effect was operational in vivo, PKH26-
labeled WT or CD312/2 HY-specific effector memory T cells
were injected intravenously (i.v.) into WT recipients, which had
received 1200 ng CXCL10 or saline solution intraperitoneally
(i.p.) prior to adoptive transfer, as we have previously described
[20]. T cells with a defined antigen specificity were used in these
experiments to rule out any interference due to antigen-induced
migration [21,22] – hence HY-specific T cells were injected into
female (non-antigenic) syngeneic recipients. Phenotypic character-
ization of WT and CD312/2 effector memory T cells did not
reveal any significant difference in the expression of the array of
molecules analyzed (Figure S3). Recruitment of labeled T cells in
the peritoneal cavity was assessed 16 hours later by flow cytometric
analysis of the peritoneal lavage. As shown in Figure 1c and d,
CXCL10-driven localization of CD312/2 T cells was signifi-
cantly enhanced compared to that by WT T cells, suggesting that
loss of CD31 signals leads to increased chemokine-driven
extravasation into non-lymphoid tissue. The proportion of WT
and CD312/2 CD4+ and CD8+ T cells in the migrated
lymphocyte population was comparable (CD4+ T cells: approx-
imately 8165% WT and 7666% in CD312/2 T cells; CD8+ T
cells: approximately 1663% WT and 1865 CD312/2 T cells),
suggesting that chemotaxis by these T cell subsets is equally
affected by CD 31 signalling.
CD31-mediated Signals Interfere with the Chemokine-
induced Akt/PKB Pathway
The main signalling pathway induced by chemokine receptor
engagement during chemokinesis involves PI3K-dependent Akt/
PKB phosphorylation [18]. As the recruitment of phosphatases is a
key feature of CD31 signalling [14], we assessed whether the
increased chemotactic activity selectively observed in memory
CD312/2 T cells correlated with alterations in Akt phosphor-
ylation. Naı¨ve and antibody-activated T cells (7-day cultures) were
exposed to 300 ng/ml CCL19/21 and CXCL10, respectively, for
2 minutes. Akt activation was then measured by staining with an
antibody recognizing Akt phosphorylated at serine residue 473. As
it is shown in Figure 2a–b, Akt phosphorylation upon chemokine
stimulation was comparable in WT and CD312/2 naı¨ve T
lymphocytes, and this was prevented by the addition of the PI3K
inhibitor Wortmannin. In contrast, Akt phosphorylation was
significantly increased in CD312/2 activated T cells exposed to
CXCL10 as compared to their WT counterpart (2c–d). The
addition of a suboptimal dose of Wortmannin (10 mg/ml) led to
inhibition of Akt phosphorylation in WT T cells, while Akt
remained largely phosphorylated in CD312/2 T cells. The
‘spread’ pAkt profiles of activated T cells are likely to reflect the
heterogeneous signalling responses of primary T cells even
following optimal activation, which have been previously reported
in a number of studies [23,24,25]. These data were further
supported by the observation that the same dose of Wortmannin
significantly inhibited chemokinesis of activated WT, but not
CD312/2, T cells (Figure 3a–b). Interestingly, despite inhibiting
chemokine-induced Akt activation in naı¨ve T cells (Figure 2a–b),
exposure to Wortmannin did not significantly diminish CCL19/
21-induced naı¨ve T cell chemotaxis (Figure 3a). In this context,
naı¨ve T cell homing to secondary lymphoid tissue has been shown
to be largely mediated by DOCK2-activation and relatively PI3K-
independent [26].
Overall, these data suggest that CD31 signals may attenuate
chemokine-induced signals by interfering with Akt phosphoryla-
tion in activated T lymphocytes.
Differential Cellular Segregation of CD31 Molecules in
Naı¨ve and Activated T Cells
The molecular basis of the different effects of CD31-mediated
regulation of chemokine-induced signals in naı¨ve and memory T
cells was further investigated by analyzing CD31 molecule
segregation in these cell types by confocal microscopy. First, naı¨ve
and activated T cells were co-stained with an antibody recognizing
LFA-1, a surface integrin which is expressed at low levels and
homogenously dispersed on the naı¨ve T cell surface, and is
upregulated and clustered in activated T cells [27]. As it is shown
in Figure 4a, in naı¨ve T cells CD31 was largely localized to the cell
membrane, where it was homogenously distributed. In contrast,
albeit downregulated, CD31 was predominantly aggregated in
large clusters in activated T cells (Figure 4b).
Confocal imaging of activated T cells migrating to CXCL10
indicated that CD31 aggregates were largely polarized to the
leading edge of migrating T cells (Figure 5 a–b), thus being ideally
placed for interference with the biochemical pathways initiated by
chemokine receptors, which also segregate to the lamellipodia of
migrating T cells [28]. In this context, co-localization of CD31
molecules and phosphatases to the leading edge in migrating
granulocytes has been previously reported [29].
Mechanisms of CD31 Triggering During Chemokinesis
A major issue raised by the observations described above
concerns the mechanism of CD31 triggering during chemokinesis.
While during trans-endothelial migration homophilic interactions
most likely occur between CD31 molecule on EC and T cell
apposing membranes, cell:cell contact is unlikely to take place
during migration through a transwell. Based on previous report
that dynamic CD31 cis-membrane interactions (i.e. clustering
within the same cell membrane) can induce signalling events in
CD31-transfected human embryonic kidney and erythroleukemia
cells [30], we reasoned that CD31 molecule segregation in
compact clusters on the memory T cell surface (Figure 4b, d)
might elicit similar effects.
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We therefore sought to investigate whether interfering with this
molecular segregation could enhance T cells response to
chemokines in the absence of intercellular CD31 engagement.
As the CD31 domain responsible for cis-interactions has not been
identified, we decided to disrupt CD31 oligomerization by steric
interference. WT naı¨ve and activated T cells were ‘rested’ in
Figure 1. CD31-deficient activated T cells display enhanced responses to chemokines in vitro and in vivo. Panels a-b: Naı¨ve and activated
WT and CD312/2 T cell migration through a transwell in response to the chemokines CCL19/21 and CXCL10, respectively, was assessed over 6 hours.
Percentage migration was calculated by dividing the number of cells in the bottom chamber by the original number of cells plated onto the
transwell. The average percentage migration from four independent experiments is shown. Error bars indicate SD (*p,0.01). Panel c: Effector memory
HY-specific WT or CD312/2 T cells were labeled with PKH26 and injected i.v. into syngeneic female mice that had received an i.p. injection of 1.2 mg
CXCL10 30 minutes earlier. Mice were sacrificed 16 hours later, and the presence of PKH26-labeled T cells in the peritoneal lavage was analysed by
flow cytometry. Due to the presence of an autofluorescent population of non-T cells often detected in FL-2, cells were double-stained with an APC-
conjugated anti-CD3 antibody. Representative dot plots are depicted on the left hand panels. The average fold-increase (T cells in chemokine-treated
animals/T cells in PBS-treated animals 6 SD) of PKH26 (FL-2)-labeled T cells gated in the CD3+ T cell population retrieved from at least five animals/
group in 3 independent experiments of similar design are shown on the right hand panels. *p,0.04.
doi:10.1371/journal.pone.0039433.g001
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serum-free medium overnight and then treated with an anti-CD31
antibody known to inhibit CD31 homophilic interactions without
inducing signalling [31], in order to prevent cis-membrane re-
clustering. An isotype-matched antibody was used as a control.
Figure 2. CD31 inhibits chemokine-induced Akt phosphorylation in activated T cells. Naı¨ve and activated T cells were exposed to CCL19/
21 and CXCL10, respectively, for 2 minutes. Phosphorylation of Akt at serine 473 was assessed by antibody staining and flow cytometry. In panels a
and c. representative histograms of the experimental conditions indicated beside each profile are shown. Panel b and d indicate cumulative data of
the mean fluorescence intensity (MFI) indicative of Akt phosphorylation obtained in the various conditions indicated in at least 4 independent
experiments of identical design. *p,0.05 **p,0.02.
doi:10.1371/journal.pone.0039433.g002
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Naı¨ve and activated T cells were then exposed to CCL19/21 and
CXCL10, respectively, in a transwell chemokinesis assay. As it is
shown in Figure 6a, antibody pre-treatment did not affect
migration of naı¨ve T cells, while anti-CD31-treated activated T
cells displayed significantly enhanced chemokinesis (Figure 5b). It
is known that hemophilic engagement of CD31 by dendritic cells
leads to functional CD31 signalling in naive T cells [15].
Together with the observation that CD31 molecules segregate
in compact clusters on activated T cell surface these data are
consistent with the hypothesis that CD31 interactions on the same
cell membrane are required to inhibit chemokinesis.
Discussion
In this study, we show that CD31 signals attenuate T cell
responses to chemokines, a previously unknown function of this
immunoreceptor. Importantly, the regulation of response to
chemokines by CD31 selectively affects primed T cells, in which
this molecule segregates in membrane clusters.
This spatial distribution favours molecular interactions on the
same cell membrane, which we propose as a mechanism inducing
CD31 signalling in polarized, migrating T cells. This hypothesis is
supported by our observation that steric interference, achieved
with a non-activating antibody, prevents modulation of T cell
chemokinesis by CD31.
Dynamic CD31 cis-membrane homophilic interactions have
been previously described in CD31-transfected human embryonic
kidney and erythroleukemia cells [30], although the molecular
domain/s mediating these interactions have not been identified.
As activated T cells do not express any other known CD31 ligand
[32], it is likely that the effect that we observe is due to CD31
interactions with itself, although we cannot formally exclude the
possibility that CD31 is associated with a different protein.
The enhanced chemokinetic responses by CD31-deficient
primed T cells correlate with increased phosphorylation of
mediators of the PI3K/Akt pathway and partial resistance to
PI3K inhibition. A key feature of CD31 is its ability to recruit
phosphatases following its engagement [14]. It is therefore likely
that CD31-dependent modulation of chemokinesis is mediated by
the recruitment of phosphatases targeting this pathway. In this
context, it has been recently reported that silencing of SHIP-1, a
phosphatase recruited by CD31 [33], leads to increased basal
phosphorylation of protein kinase B (PKB)/Akt and its substrate
GSK3b, as well as an increase in basal levels of polymerized actin
following chemokine stimulation of primary activated human T
cells [34].
In naı¨ve T cells, despite being expressed at higher levels, CD31
is evenly distributed on the cell surface, and does not interfere with
chemokine induced Akt phosphorylation. Similarly, naı¨ve T cell
responsiveness to chemokines is unaffected by loss of CD31
signals. In line with this observation, naı¨ve T cell numbers and
distribution are unaffected by genetic deletion of CD31 [2,16].
The physiological relevance of the distinct effects of CD31
signalling on naı¨ve and activated T cell responsiveness to
chemokines must lay, in our view, in their different trafficking
patterns and proliferative potential. Naı¨ve T cells continuously
recirculate through secondary lymphoid tissue in response to
constitutively SLO-expressed chemokines such as CCL19 and
CCL21 [35]. This type of trafficking does not generate inflam-
mation. However, CD31 signalling becomes functional in naı¨ve T
cells when engaged in trans by dendritic cells, with the effect of
modulating their excessive expansion during priming [15].
Upon antigen activation, T cells are re-programmed to
respond to inflammation-induced chemokines, such as CXCL10,
which allow them to gain access to non-lymphoid tissue where
they can induce damage [35]. The proliferative potential of
memory T cells is much reduced as compared to that of naı¨ve T
cells and possibly does not require substantial regulation for
homeostatic purposes.
Thus, we propose that CD31 regulatory activity is optimised
by its ability to affect distinct, but equally important functions of
memory and naı¨ve T cells. Together with its role as a regulator
of T cell activation and survival following T cell priming [15],
CD31-mediated attenuation of memory T cell chemokinesis
defines this molecule as a unique multifunctional immunoregu-
latory receptor.
The clinical relevance of these observations applies to a variety
of inflammatory conditions including autoimmunity, allograft
Figure 3. CD31-deficient T cell chemokinesis is partially resistant to PI3K inhibition. Naı¨ve (panel a) and activated (panel b) WT and
CD312/2T cell migration in response to either CCL19/21 (naı¨ve) or CXCL10 (activated) through a transwell was assessed as described in Methods.
Some T cells were pre-incubated with the PI3K inhibitor Wortmannin (10 mM) for 30 minutes at RT. Percentage migration was calculated by dividing
the number of cells harvested from the bottom chamber following 6 hours incubation at 37uC by the original number of cells plated onto the
transwell. The average percentage migration from at least three independent experiments is shown. Error bars indicate SD (*p,0.01).
doi:10.1371/journal.pone.0039433.g003
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rejection, and the response to pathogens. CD31 polymorphisms
affecting its binding site and cyoplasmic ITIMs correlate with
increased GVHD and atherosclerosis severity [7,8,9,10,11,12,13].
It has been hypothesized that these mutations may influence
CD31 binding affinity, structure and signalling capacity [36].
Hence, the possibility that these polymorphisms might affect
Figure 4. CD31 molecules segregate differently in naı¨ve and activated T lymphocytes. Confocal images of naive WT T cells stained with
rabbit-anti-mouse CD31 (green fluorescence) and rat anti- mouse LFA-1 (red fluorescence) followed by incubation with secondary antibodies Alexa
Fluor 488-conjugated donkey anti-rabbit IgG and Alexa Fluor 647-conjugated goat anti-rat IgG, respectively, are shown in panel a. Added scale
bar = 6 mm. Panel b: WT Activated T cells generated via anti-CD3 and anti-CD28 treatment over 7 days were allowed to rest for 24 hours in low serum
and then fixed. LFA-1 and CD31 expression was visualized as described above. Added scale bar = 6 mm. The average CD31 distribution/expression (6
SD) from at least four 636magnified fields obtained in three independent experiments of identical design is shown in panel c (*p,0.001).
doi:10.1371/journal.pone.0039433.g004
Figure 5. Polarization of CD31 molecules in activated T cells following exposure to chemokines. Activated WT T cells were allowed to
migrate through transwells in response to the chemokine CXCL-10 (panel a) or incubated in medium alone (panel b) and then fixed for analysis. Cells
were not permeabilized to allow surface staining only. Confocal images of T cells stained with rabbit-anti-mouse CD31 followed by incubation with
Alexa Fluor 488-conjugated donkey anti-rabbit IgG are shown in panels a and b. A higher magnification of a migrating lymphocyte further depicting
CD31 molecule polarization is shown in panel c. Confocal z stacks series were acquired using a step size of 0.5 mm. Added scale bar = 6 mm. The
average CD31 distribution/expression (6 SD) from at least four 636magnified fields obtained in three independent experiments of identical design is
shown in panel b (*p,0.001).
doi:10.1371/journal.pone.0039433.g005
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CD31-mediated regulation of T cell function and thus contribute
to the impact of T cell inflammation will require prompt
investigation and careful analysis of CD31 polymorphisms in a
variety of T cell mediated diseases. Importantly, a recent report
that CD31 activity can be enhanced by peptide ligation in human
T cells [37], together with our observations paves the way for the
therapeutic manipulation of this molecule in the control of T cell-
mediated inflammation.
Methods
Ethics Statement
This study was carried out in strict accordance with the Home
Office recommendations and under its authority following
approval by the Imperial College London/Central Biomedical
Services ethics committee (REF. PPL 70/5872).
Mice
CD312/2 and wild type (WT) mice were generated as
previously described [2] and used at the age of 8–10 weeks.
Reagents
APC-conjugated anti-mouse CD3 was obtained from Caltag
Laboratories (Burlingame, CA, USA). Polyclonal Anti-Phospho
Akt (Ser473) was obtained from Cell Signalling Technology (New
England Biolabs, Hertfordshire, UK) while rat anti-mouse CD31
(clone 390), an antibody shown to interfere with CD31-mediated
cell aggregation [31], was purchased from eBioscience, Ltd.
(Hatfield, UK). All the other antibodies used in this study were
purchased form BD Biosciences unless specified otherwise. The
cell linker PKH26 was purchased from Sigma-Aldrich (Gilling-
ham, Dorset, UK). For T cell labeling, PKH26 was added at a
final concentration of 5 mM. CXCL-10, CCL19 and CCL21
chemokines were purchased from PeproTech (London, UK).
Wortmannin was obtained from Sigma-Aldrich.
HY-specific Effector Memory T Cells and Activated T Cells
Effector memory CD4+ and CD8+ T cells specific for the male-
specific minor transplantation antigen HY peptide Dby epitope
and restricted by H2-Ab and for the Uty epitope restricted by H2-
Db, respectively, were obtained from WT and CD312/2 mice by
2 fortnightly intraperitoneal (i.p.) immunization of female mice
with male splenocytes, and further expansion with male spleno-
cytes in vitro, as previously described [21,22]. Both T cell
populations were composed by approximately 20% CD8+ and
75% CD4+ T cells which displayed similar phenotypes (Figure S3).
These cells are referred as to effector memory T cells throughout
the text.
Activated T cells were obtained by polyclonal stimulation of LN
cells with plate-bound anti-CD3 (1 mg/ml, eBiosciences, Hatfield,
UK) and anti-CD28 (5 mg/ml, eBiosciences, Hatfield, UK) in
RPMI 1640 supplemented with 10%FCS, 2 mM glutamine,
50 IU/ml penicillin, 50 mg/ml streptomycin, 50 mM 2-mercapto-
ethanol, 20 mM HEPES, 1 mM sodium pyruvate and 20 U/ml
recombinant IL-2 (Roche, West Sussex, UK) for 7 days at 37uC.
CD31 expression by activated T cells was down regulated
compared to that of naı¨ve T cells (data not shown, and
Figure 3a–d), as previously described [15,38]. These cells are
referred as to activated T cells throughout the text.
Chemokinesis assays. For chemokinesis assays, T cells were
seeded (52106105/well) in the upper chamber of a 5 mm-pore
polycarbonate Transwell (Costar). A 0.7 ml volume of the
chemokinesis medium (RPMI 0.5% FCS) containing either
CXCL10 (300 ng/ml), or CCL19 (200 ng/ml) and CCL21
(200 ng/ml) was added to the bottom chamber, while 0.3 ml of
cell suspension was added to the top chamber. Transwells were
incubated for 6 hours at 37uC with 5% CO2. The number of
migrated cells was evaluated using CountBrightTM absolute
counting beads (Molecular probes) and flow cytometry. Results
are expressed as percentage of transmigrated cells.
Peritoneal T Cell Recruitment by Chemokines
Labeled T cells (107/mouse) were injected i,v, into syngeneic
female mice received an i.p. injection of CXCL10 (1200 ng)
immediately prior to the adoptive transfer. Enrichment of labeled
T cells in the peritoneal lavage was assessed 16 hours later by flow
cytometry using a FACSCalibur (Becton Dickinson, Mountain
Figure 6. Antibody-mediated CD31 ‘immobilization’ enhances activated T cell chemokinesis. Naı¨ve (a) and activated (b) WT T cells were
incubated overnight in RPMI 0.5% FCS. Some T cells were pre-incubated with an anti-CD31 mAb at saturating concentrations (5 mg/ml) for 30
minutes at RT. Migration in response to CXCL10 or medium through a transwell was assessed over 6 hours. Percentage migration was calculated by
dividing the number of cells harvested from the bottom chamber following 6 hours incubation at 37uC by the original number of cells plated onto
the transwell. The average percentage migration from three independent experiments is shown. Error bars indicate SD (*p,0.05).
doi:10.1371/journal.pone.0039433.g006
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View, CA) and FlowJo version 7.1.2 software (Tree Star Inc,
Ashland, OR, USA).
Measurement of AKT/PKB Phosphorylation
Naı¨ve or activated T cells from WT and CD312/2 mice were
‘rested’ in RPMI 1640 medium supplemented with 10% FCS at
37uC overnight before stimulation with 300 ng/ml CCL21/
CCL19 for naı¨ve T cells and 300 ng/ml CXCL-10/IP-10 for
activated T cells. Cells were harvested at the indicated time points,
fixed with 2% PFA for 15 min at 37uC, washed twice with PBS,
permeabilized with 90% ice-cold methanol for 10 min at 220uC
then washed twice with PBS. Intracellular staining was carried out
after initially blocking permeabilized cells in RT FACS buffer
(0.5% BSA/PBS + Na3VO4) for 30 min and incubation with a
dilution of 1:100 of Phospho-Akt (Ser473) rabbit anti-mouse
antibody (Cell Signalling Technology) for 30 min at room
temperature. Cells were washed and stained with secondary
APC-F(ab)2 fragment donkey anti-rabbit IgG (H+L) (Jackson
ImmunoResearch, Suffolk, UK) at 1:100 for 30 min at room
temperature. Cells were then analyzed using flow cytometry.
Confocal Imaging
Cells were allowed to adhere onto poly-l-lysine coated
coverslips, fixed in 4% paraformaldehyde and permeabilized
using 0.2% Triton X-100 (Sigma-Aldrich, Gillingham, UK) in
PBS. In experiments using T cells exposed to chemokines,
permeabilization was not performed in order to facilitate the
detection of membrane CD31. Following fixation cells were
washed in PBS, blocked in blocking buffer (PBS containing
0.1%Fish skin gelatin and 1% FCS) and then stained with rabbit
anti-mouse for CD31 (Novus Biologicals, Cambridge, UK) and rat
anti- mouse LFA-1 (eBioscience, Ltd., Hatfield, UK). Following
staining, cells were washed again and stained with secondary
antibodies Alexa Fluor 488-conjugated donkey anti-rabbit IgG
and Alexa Fluor 647-conjugated goat anti-rat IgG (Invitrogen,
Paisley, UK). Coverslips were mounted onto slides and then
examined using an Leica SP5 confocal microscope equipped with
a 6361.4 NA objective. Confocal images and z-stacks were
acquired and analyzed by Leica LAS software. Repositioning of
scale bars and image layouts were prepared using Adobe
Photoshop. All images in a group were treated equally.
Statistical Analysis
The Student’s t-Test test was used do assess significance of all
experiments presented. All reported p-values are two-sided. A p
value .0.05 was considered significant.
Supporting Information
Figure S1 Phenotype of WT and CD31-deficient naı¨ve
and activated T cells. WT and CD312/2 naı¨ve (panel a) and
activated (anti-CD3 plus anti-CD28, 7 days, panel b) T cells were
stained with the indicated antibodies (solid line). T cells were
incubated with an isotype-matched antibody as a control (grey
line). Expression of indicated molecules was analyzed by flow
cytometry.
(TIF)
Figure S2 Chemokinesis by WT and CD312/2 activat-
ed T cells in response to CXCL12. Activated WT and
CD312/2 T cell migration through a transwell in response to the
chemokine CXCL12 (100 ng/ml) was assessed over 6 hours.
Percentage migration was calculated by dividing the number of
cells in the bottom chamber by the original number of cells plated
onto the transwell. The average percentage migration from three
independent experiments is shown. Error bars indicate SD
(*p,0.01).
(TIF)
Figure S3 Phenotype of HY-specific WT and CD312/2
T cells. Expression of the molecules indicated above each set of
panels by WT and CD312/2 HY-specific T cells was assessed at
the time of injection (i.e., 7–10 days following re-stimulation in
vitro) by flow cytometry. Staining with an isotype-matched control
antibody is indicated by the light grey profiles.
(TIF)
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